MindMed Provides Overview of Clinical Progress and Corporate Updates at Investor Day
20 Junho 2023 - 9:30AM
Business Wire
Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED),
(the “Company” or “MindMed”), a clinical stage biopharmaceutical
company developing novel product candidates to treat brain health
disorders, will provide an overview of clinical progress and
corporate updates during an Investor Day today focused primarily on
the MM-120 (lysergide D-tartrate) program in generalized anxiety
disorder (GAD).
The Investor Day will begin at 9:30 a.m. ET. Investors can
register here. Audio webcasts and replays of available
presentations will be accessible on MindMed’s Investor Resources
website for up to 90 days following the event.
The event will feature presentations from management and four
subject matter experts, including:
-- Maria Oquendo, MD (University of Pennsylvania School of
Medicine), who will discuss the unmet need and patient journey in
GAD
-- David Feifel, MD, PhD (Kadima Neuropsychiatry Institute), who
will discuss the practical aspects of administering monitored
therapies
-- Michael Kobernick, MD (Blue Cross/Blue Shield Michigan), who
will review payer considerations in new medication coverage
-- W. Chad Shear, Esq (Cooley LLP), who will discuss the
intellectual property landscape
As part of the Investor Day, the Company will be reiterating its
guidance that the Phase 2b trial evaluating MM-120 for the
treatment of GAD remains on track for a late 2023 topline data
readout. This Phase 2b trial is a multi-center, parallel,
randomized, double-blind, placebo-controlled, dose-optimization
study. The participants are randomized to receive a single
administration of 25 µg, 50 µg, 100 µg or 200 µg of MM-120 or
placebo. The primary objective is to determine the reduction in
anxiety symptoms four weeks after a single administration of
MM-120, compared across the five treatment arms. Key secondary
objectives, measured up to 12 weeks after the single
administration, include assessments of anxiety symptoms, safety and
tolerability, as well as other measures of efficacy and quality of
life. More information about the trial is available on our website
(mindmed.co), the trial website (anxietyresearchstudy.com) or on
clinicaltrials.gov (identifier NCT05407064). In May 2023, the
Company reported that over 50% of the target study population has
been enrolled and dosed.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing
novel product candidates to treat brain health disorders. Our
mission is to be the global leader in the development and delivery
of treatments that unlock new opportunities to improve patient
outcomes. We are developing a pipeline of innovative product
candidates, with and without acute perceptual effects, targeting
neurotransmitter pathways that play key roles in brain health
disorders.
MindMed trades on NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the symbol MMED.
Forward-Looking Statements
Certain statements in this news release related to the Company
constitute “forward-looking information” within the meaning of
applicable securities laws and are prospective in nature.
Forward-looking information is not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as “will”, “may”, “should”, “could”,
“intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”,
“potential” or “continue”, or the negative thereof or similar
variations. Forward-looking information in this news release
includes, but is not limited to, statements regarding the upcoming
Investor Day, anticipated results and timing of clinical trials,
including the timing of the topline data readout of the MM-120
Phase 2b trial in GAD, and the potential benefits of the Company’s
product candidates. There are numerous risks and uncertainties that
could cause actual results and the Company’s plans and objectives
to differ materially from those expressed in the forward-looking
information, including history of negative cash flows; limited
operating history; incurrence of future losses; availability of
additional capital; lack of product revenue; compliance with laws
and regulations; difficulty associated with research and
development; risks associated with clinical trials or studies;
heightened regulatory scrutiny; early stage product development;
clinical trial risks; regulatory approval processes; novelty of the
psychedelic inspired medicines industry; as well as those risk
factors discussed or referred to herein and the risks described in
the Company’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2022 under headings such as “Special Note Regarding
Forward-Looking Statements,” and “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations” and other filings and furnishings made by the Company
with the securities regulatory authorities in all provinces and
territories of Canada which are available under the Company’s
profile on SEDAR at www.sedar.com and with the U.S. Securities and
Exchange Commission on EDGAR at www.sec.gov. Except as required by
law, the Company undertakes no duty or obligation to update any
forward-looking statements contained in this release as a result of
new information, future events, changes in expectations or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230620175796/en/
For Media & Investor Inquiries, please contact: Maxim
Jacobs, CFA Vice President, Investor Relations and Corporate
Communications Mind Medicine (MindMed) Inc. ir@mindmed.co
media@mindmed.co
Mind Medicine MindMed (NASDAQ:MNMD)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Mind Medicine MindMed (NASDAQ:MNMD)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024